ICON partners with US Government for clinical trials of Covid-19 vaccines

2023-09-14
Pharmaceutical Technology
疫苗临床研究免疫疗法
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
来源: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
来源: Pharmaceutical Technology
The US government has plans to invest over $5bn in the Project NextGen programme. Image Credit: PopTika / Shutterstock.
US Biomedical Advanced Research and Development Authority (BARDA) has partnered with Ireland-based ICON to conduct clinical trials of Covid-19 vaccine candidates selected as part of “Project NextGen”.
A part of the US Government’s Strategic Preparedness and Response division, BARDA has launched Project NextGen to develop Covid-19 vaccines and therapies for current and future strains. To achieve this, BARDA plans to leverage its public-private partnerships. The government has plans to invest more than $5bn in the Project NextGen programme.
Recommended Reports
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - PBMC vaccine in Vaginal Cancer GlobalData
ICON partners with US Government for clinical trials of Covid-19 vaccines
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - PBMC vaccine in Penile Cancer GlobalData
View allCompanies IntelligenceICON PlcEmergent BioSolutions IncRegeneron GmbHThe U.S. governmentView all
In June, the European Medicines Agency (EMA) identified the need to update the Covid-19 vaccines to include the XBB Omicron variant. The US Government seconded that sentiment, and last month, BARDA partnered with Regeneron to develop a Covid-19 monoclonal antibody vaccine candidate.
ICON’s government and public health solutions team will conduct a Phase IIb active comparator clinical trial to evaluate the efficacy of the next-generation Covid-19 vaccineCovid-19 vaccine, selected by BARDA, compared to the currently approved/authorised vaccines. The trial is expected to enrol 10,000 volunteers over a six-month period.
Although the Covid-19 trial activity has significantly decreased in the last two years, several trials have been initiated in 2023. As per GlobalData’s clinical trial database, more than 80 trials have been initiated for Covid-19 indication in the US and over 400 trials globally this year.
GlobalData is the parent company of Pharmaceutical Technology.
ICON previously partnered with Evergreen Therapeutics to develop a Covid-19 drug therapy in 2021. The Ireland-based company also has a patent engagement platform that increased patient outreach and enrolment.
ICON has previously partnered with BRADA to conduct a clinical trial for an anthrax vaccine, AV7909. The vaccine comprises Emergent BioSolutions’s Biothrax combined with an immune system stimulant or adjuvant.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。